Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings results on February 17, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $1.70, beating the consensus estimate of $1.61 by $0.09 per share. Revenue came in at $107.1M, beating the estimate of $106.5M.
Krystal Biotech's stock moved following the earnings release. The stock currently trades at $288.35 with a market capitalization of $7.2B.